Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
STOCKHOLM, September 16, 2013 /PRNewswire/ --
Explore cutting-edge Nordic science and technologies
Register for your free media pass
SwedenBIO, in conjunction with its sister organisations in Denmark, Finland and Norway, invites you to attend Nordic Life Science Days 2013, the Nordic's only international investor, partnering and networking life science meeting.
With focused academic resources and support from both the local investment community and government, the Nordic area is well placed to exhibit itself as a European life science hotspot. Nordic Life Science Days will showcase this innovation and highlight the best of the region's pharmaceutical, biotechnology, diagnostic, medtech and digital health industries.
Join Dr Brogren, Director General of VINNOVA - the Swedish Governmental Agency for Innovative Systems for Challenge Driven Innovation for Future Health.
Stockholm Uppsala Focus - Collaborative Business Models - Do's and Don'ts, a session hosted by Stockholm Science City Foundation and with speakers for AstraZeneca, Xbrane Bioscience, Affibody and Athera, spotlights open innovation and collaborations as a business model.
The Early Financing session focuses on EU funding, public programmes for support of innovative SMEs, working with foundations as a source of funding and crowd funding, bringing together speakers from academia, angel funds and charities.
UppsalaBIO is hosting Hoffman-La Roche, Efpia, H. Lundbeck A/S and Sanofi Paster for a discussion on The Arena for Successful Innovation.
To register for the event, visit http://www.nlsdays.com. The SwedenBIO partnering system closes on 1st October 2013 and registration on 10 October 2013.
To register for your free media pass, please email email@example.com.
©2012 PR Newswire. All Rights Reserved.